

Matthew L Meyerson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6766283/matthew-l-meyerson-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174 papers	84,556 citations	88 h-index	187 g-index
187 ext. papers	104,814 ext. citations	22 avg, IF	6.92 L-index

#	Paper	IF	Citations
174	Long-read sequencing reveals complex patterns of wraparound transcription in polyomaviruses.. <i>PLoS Pathogens</i> , 2022 , 18, e1010401	7.6	1
173	Quantification of aneuploidy in targeted sequencing data using ASCETS. <i>Bioinformatics</i> , 2021 , 37, 2461-2463	24.3	4
172	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline T790M Mutation. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100146	1.4	
171	Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. <i>Nature Genetics</i> , 2021 , 53, 881-894	36.3	6
170	Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. <i>Cancer Discovery</i> , 2021 , 11, 591-598	24.4	20
169	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021 , 27, 1695-1705	12.9	9
168	Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells. <i>Science Immunology</i> , 2021 , 6,	28	2
167	Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021 , 34, 108707	10.6	7
166	Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma. <i>Gut</i> , 2021 ,	19.2	2
165	Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. <i>Nature Communications</i> , 2021 , 12, 4375	17.4	7
164	Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. <i>Genome Medicine</i> , 2021 , 13, 114	14.4	2
163	Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. <i>Journal of Biological Chemistry</i> , 2020 , 295, 3431-3446	5.4	6
162	Mutational signature in colorectal cancer caused by genotoxic pks E. coli. <i>Nature</i> , 2020 , 580, 269-273	50.4	286
161	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 2556-2564	12.9	32
160	Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. <i>Nature Cancer</i> , 2020 , 1, 235-248	15.4	137
159	Genomic basis for RNA alterations in cancer. <i>Nature</i> , 2020 , 578, 129-136	50.4	148
158	Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma. <i>Molecular Cancer Research</i> , 2020 , 18, 574-584	6.6	13

157	Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2. <i>Genome Medicine</i> , 2020 , 12, 108	14.4	22
156	Bacterial invaders drive CRC progression. <i>Science Signaling</i> , 2020 , 13,	8.8	1
155	Illuminating the noncoding genome in cancer.. <i>Nature Cancer</i> , 2020 , 1, 864-872	15.4	14
154	Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 535-539	5	8
153	Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. <i>Blood Advances</i> , 2020 , 4, 1006-1011	7.8	3
152	Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. <i>Nature Communications</i> , 2019 , 10, 3991	17.4	199
151	Commensal Microbiota Promote Lung Cancer Development via T _H Cells. <i>Cell</i> , 2019 , 176, 998-1013.e16	56.2	290
150	Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019 , 79, 1038-1040	10.1	2
149	Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing. <i>ACS Medicinal Chemistry Letters</i> , 2019 , 10, 1537-1542	4.3	7
148	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019 , 17, 2281-2293	6.6	15
147	Genomic and immune profiling of pre-invasive lung adenocarcinoma. <i>Nature Communications</i> , 2019 , 10, 5472	17.4	56
146	Identification and Characterization of Oncogenic Mutations in Lung Adenocarcinoma. <i>Molecular Cancer Research</i> , 2019 , 17, 1002-1012	6.6	18
145	Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia. <i>Experimental Hematology</i> , 2019 , 69, 37-42	3.1	7
144	Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants. <i>International Journal of Cancer</i> , 2018 , 143, 679-685	7.5	7
143	RAS-MAPK Reactivation Facilitates Acquired Resistance in -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1526-1539	6.1	27
142	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018 , 173, 371-385.e18	56.2	854
141	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018 , 173, 386-399.e12	46.2	133
140	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018 , 173, 321-337.e10	56.2	1124

139	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018 , 23, 194-212.e6	10.6	146
138	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
137	Mechanistic Insights into Transmissible Cancers of Mammals. <i>Cancer Cell</i> , 2018 , 33, 543-544	24.3	2
136	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018 , 24, 679-690	50.5	659
135	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018 , 6, 282-300.e2	10.6	159
134	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	24.3	377
133	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
132	SvABA: genome-wide detection of structural variants and indels by local assembly. <i>Genome Research</i> , 2018 , 28, 581-591	9.7	149
131	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018 , 32, 1838-1841	10.7	24
130	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. <i>Cancer Discovery</i> , 2018 , 8, 59-73	24.4	67
129	Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. <i>Cancer Discovery</i> , 2018 , 8, 108-125	24.4	67
128	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E8388-E8394	11.5	29
127	Genetic and transcriptional evolution alters cancer cell line drug response. <i>Nature</i> , 2018 , 560, 325-330	50.4	379
126	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018 , 23, 3392-3406	10.6	200
125	Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. <i>Cell</i> , 2018 , 174, 433-447.e19	56.2	155
124	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018 , 3,	9.9	21
123	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018 , 3,	9.9	49
122	Bifidobacterium Genus in Colorectal Carcinoma Tissue in relation to Tumor Characteristics and Patient Survival. <i>FASEB Journal</i> , 2018 , 32, 407.3	0.9	

121	Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. <i>Nature Communications</i> , 2018 , 9, 5450	17.4	83
120	The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. <i>American Journal of Pathology</i> , 2018 , 188, 2839-2852	5.8	31
119	Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	36
118	Mutational processes shape the landscape of TP53 mutations in human cancer. <i>Nature Genetics</i> , 2018 , 50, 1381-1387	36.3	165
117	in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. <i>Cancer Immunology Research</i> , 2018 , 6, 1327-1336	12.5	78
116	Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. <i>Nature Genetics</i> , 2018 , 50, 937-943	36.3	35
115	Insertions and Deletions Target Lineage-Defining Genes in Human Cancers. <i>Cell</i> , 2017 , 168, 460-472.e14	56.2	75
114	Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. <i>JAMA Oncology</i> , 2017 , 3, 801-809	13.4	51
113	Molecular Biology, Genomics, Proteomics, and Mouse Models of Human Cancer 2017 , 1-31		
112	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017 , 169, 1327-1341.e23	56.2	1125
111	Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. <i>Cancer Research</i> , 2017 , 77, 4498-4505	10.1	38
110	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017 , 171, 540-556.e25	57.2	961
109	Analysis of persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017 , 358, 1443-1448	33.3	578
108	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017 , 8, 1324	17.4	314
107	Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. <i>Gut</i> , 2016 , 65, 1973-1980	19.2	454
106	Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. <i>Clinical Cancer Research</i> , 2016 , 22, 250-8	12.9	113
105	Copy number alterations unmasked as enhancer hijackers. <i>Nature Genetics</i> , 2016 , 49, 5-6	36.3	25
104	Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. <i>Clinical and Translational Gastroenterology</i> , 2016 , 7, e200	4.2	156

103	Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. <i>Cancer Biology and Therapy</i> , 2016 , 17, 1274-1281	4.6	8
102	Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. <i>Science Translational Medicine</i> , 2016 , 8, 363ra147	17.5	93
101	Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. <i>Cancer Discovery</i> , 2016 , 6, 914-29	24.4	343
100	Metagenomic Characterization of Microbial Communities Within the Deeper Layers of the Ileum in Crohn's Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016 , 2, 563-566.e5	7.9	16
99	Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. <i>Nature Genetics</i> , 2016 , 48, 176-82	36.3	210
98	Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. <i>Nature Chemical Biology</i> , 2016 , 12, 102-8	11.7	51
97	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016 , 164, 550-63	56.2	1140
96	Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. <i>Molecular Cancer Research</i> , 2016 , 14, 207-15	6.6	16
95	Comprehensive Genetic Interrogation of Circulating Multiple Myeloma Cells at Single Cell Resolution. <i>Blood</i> , 2016 , 128, 800-800	2.2	
94	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016 , 1, e87062	9.9	245
93	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. <i>PLoS Genetics</i> , 2016 , 12, e1006242	6	62
92	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016 , 29, 723-736	36.3	324
91	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. <i>Nature Genetics</i> , 2016 , 48, 607-16	36.3	613
90	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015 , 372, 2481-98	59.2	1828
89	Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). <i>Journal of Thoracic Oncology</i> , 2015 , 10, 838-843	8.9	113
88	Calibrating genomic and allelic coverage bias in single-cell sequencing. <i>Nature Communications</i> , 2015 , 6, 6822	17.4	57
87	Pugh et al. reply. <i>Nature</i> , 2015 , 520, E12-4	50.4	8
86	BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. <i>Nucleic Acids Research</i> , 2015 , 43, e19	20.1	110

85	Prospective derivation of a living organoid biobank of colorectal cancer patients. <i>Cell</i> , 2015 , 161, 933-45	56.2	1215
84	A functional landscape of resistance to ALK inhibition in lung cancer. <i>Cancer Cell</i> , 2015 , 27, 397-408	24.3	123
83	Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. <i>ACS Chemical Biology</i> , 2015 , 10, 2687-96	4.9	28
82	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015 , 5, 1164-1177	24.4	581
81	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015 , 163, 1011-25	56.2	1713
80	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the B-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. <i>Journal of Physical Education and Sports Management</i> , 2015 , 1, a000539	2.8	40
79	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015 , 163, 506-19	56.2	1055
78	NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2382-2389	6.1	28
77	Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. <i>Nature Structural and Molecular Biology</i> , 2015 , 22, 703-711	17.6	56
76	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015 , 1, 662-7	13.4	53
75	Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. <i>Cancer Research</i> , 2015 , 75, 264-9	10.1	224
74	Malawi polyomavirus is a prevalent human virus that interacts with known tumor suppressors. <i>Journal of Virology</i> , 2015 , 89, 857-62	6.6	18
73	The tumor virus landscape of AIDS-related lymphomas. <i>Blood</i> , 2015 , 125, e14-22	2.2	51
72	Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 606-15	5	84
71	Oncotator: cancer variant annotation tool. <i>Human Mutation</i> , 2015 , 36, E2423-9	4.7	332
70	Chromothripsis from DNA damage in micronuclei. <i>Nature</i> , 2015 , 522, 179-84	50.4	635
69	Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. <i>International Journal of Cancer</i> , 2015 , 137, 776-83	7.5	33
68	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. <i>Genome Research</i> , 2015 , 25, 316-27	9.7	240

67	Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. <i>Molecular Cancer Research</i> , 2015 , 13, 689-98	6.6	39
66	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4521-4521	2.2	1
65	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. <i>Nature Biotechnology</i> , 2014 , 32, 479-84	44.5	434
64	Targeted genomic rearrangements using CRISPR/Cas technology. <i>Nature Communications</i> , 2014 , 5, 3728	17.4	203
63	Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. <i>Genome Research</i> , 2014 , 24, 1053-63	9.7	147
62	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014 , 506, 371-5	50.4	541
61	Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature</i> , 2014 , 505, 495-501	50.4	1990
60	Characterization of HPV and host genome interactions in primary head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 15544-9	11.5	229
59	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , 2014 , 26, 319-330	24.3	521
58	Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor. <i>Angewandte Chemie</i> , 2014 , 126, 203-208	3.6	26
57	A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. <i>PLoS ONE</i> , 2014 , 9, e87361	3.7	112
56	Genetic modifiers of EGFR dependence in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 18661-6	11.5	37
55	EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. <i>Cancer Discovery</i> , 2014 , 4, 956-71	24.4	199
54	Integrated genomic characterization of papillary thyroid carcinoma. <i>Cell</i> , 2014 , 159, 676-90	56.2	1660
53	Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. <i>Cancer Research</i> , 2014 , 74, 4676-84	10.1	29
52	Oncogenic ARAF as a new driver in lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11034-11034	11.034	1
51	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013 , 500, 415-21	50.4	5895
50	Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. <i>Cell Host and Microbe</i> , 2013 , 14, 207-15	23.4	1275

49	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , 2013 , 5, 216ra177	17.5	313
48	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
47	Pan-cancer patterns of somatic copy number alteration. <i>Nature Genetics</i> , 2013 , 45, 1134-40	36.3	1198
46	Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. <i>Cancer Research</i> , 2013 , 73, 6770-9	10.1	61
45	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. <i>Cell</i> , 2013 , 152, 714-26	56.2	1006
44	Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. <i>Nature Biotechnology</i> , 2013 , 31, 213-9	44.5	2830
43	Punctuated evolution of prostate cancer genomes. <i>Cell</i> , 2013 , 153, 666-77	56.2	862
42	Mutational heterogeneity in cancer and the search for new cancer-associated genes. <i>Nature</i> , 2013 , 499, 214-218	50.4	3616
41	Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. <i>Genome Research</i> , 2013 , 23, 228-35	9.7	109
40	SF3B1 Mutation Alters The Selection Of 3SRNA Splice Sites In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 117-117	2.2	1
39	High Throughput Sequencing-Based Pathogen Discovery In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 5322-5322		
38	Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. <i>Cell</i> , 2012 , 150, 1107-1110	50.4	1304
37	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1104-10	36.3	919
36	Absolute quantification of somatic DNA alterations in human cancer. <i>Nature Biotechnology</i> , 2012 , 30, 413-21	44.5	1229
35	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. <i>Nature Genetics</i> , 2012 , 44, 685-9	36.3	1079
34	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. <i>Nature</i> , 2012 , 483, 603-7	50.4	4648
33	Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. <i>Genome Research</i> , 2012 , 22, 292-8	9.7	1165
32	Next-Generation Sequencing for the Identification of Transplantation-Associated Pathogens. <i>Blood</i> , 2012 , 120, LBA-4-LBA-4	2.2	1

31	The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 5-5	2.2	
30	PathSeq: software to identify or discover microbes by deep sequencing of human tissue. <i>Nature Biotechnology</i> , 2011 , 29, 393-6	44.5	213
29	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. <i>Genome Biology</i> , 2011 , 12, R41	18.3	1614
28	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011 , 43, 964-968	36.3	242
27	Cancer genomes evolve by pulverizing single chromosomes. <i>Cell</i> , 2011 , 144, 9-10	56.2	79
26	High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. <i>Nature Biotechnology</i> , 2011 , 29, 1109-13	44.5	162
25	Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. <i>Cancer Research</i> , 2011 , 71, 7587-96	10.1	62
24	The genomic complexity of primary human prostate cancer. <i>Nature</i> , 2011 , 470, 214-20	50.4	984
23	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011 , 471, 467-72	50.4	1117
22	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. <i>Blood</i> , 2011 , 118, 463-463		
21	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010 , 463, 899-905	50.4	2590
20	Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. <i>Cancer Cell</i> , 2010 , 17, 98-110	24.3	4782
19	SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 253-9	5	33
18	Characterizing the cancer genome in lung adenocarcinoma. <i>Nature</i> , 2007 , 450, 893-8	50.4	900
17	Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. <i>Cancer Cell</i> , 2007 , 11, 217-27	24.3	779
16	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. <i>Cancer Biology and Therapy</i> , 2007 , 6, 661-7	4.6	72
15	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 886-886	2.2	
14	Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. <i>PLoS Medicine</i> , 2006 , 3, e485	11.6	242

13	Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. <i>PLoS Medicine</i> , 2005 , 2, e313	11.6	527
12	Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. <i>Nucleic Acids Research</i> , 2004 , 32, e71	20.1	236
11	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. <i>Science</i> , 2004 , 304, 1497-500	33.3	7937
10	Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types. <i>Molecular Cancer Research</i> , 2004 , 2, 489-494	6.6	33
9	Human genetic variation and disease. <i>Lancet, The</i> , 2003 , 362, 259-60	40	4
8	Telomerase activation, cellular immortalization and cancer. <i>Annals of Medicine</i> , 2001 , 33, 123-9	1.5	103
7	Recurrent allelic deletions of chromosome arms 15q and 16q in human small cell lung carcinomas. <i>Genes Chromosomes and Cancer</i> , 2000 , 27, 323-31	5	17
6	Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. <i>Nature Biotechnology</i> , 2000 , 18, 1001-5	44.5	259
5	Inhibition of telomerase limits the growth of human cancer cells. <i>Nature Medicine</i> , 1999 , 5, 1164-70	50.5	883
4	SvABA: Genome-wide detection of structural variants and indels by local assembly		5
3	Genomic basis for RNA alterations revealed by whole-genome analyses of 27 cancer types		10
2	The Tangent copy-number inference pipeline for cancer genome analyses		3
1	Non-oncology drugs are a source of previously unappreciated anti-cancer activity		6